Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTL201
- Development stage
- Phase 2
- Lead developer
- PhytoTech Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PTL201** is an investigational oral, gastro-resistant fixed-dose cannabinoid capsule developed for **multiple sclerosis-associated spasticity**. Each capsule used in the registered Phase II study contained 5 mg tetrahydrocannabinol and 5 mg cannabidiol in seamless gelatin-matrix beadlets. The program was designed to assess safety, tolerability, pharmacokinetics, and symptomatic efficacy versus placebo, with a pharmacokinetic comparison against buccal Sativex. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03005119?tab=table))
- Other names
- PTL-201PTL201PTL 201
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on PTL201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTL201.